Roche Holding AG
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after Roche announced po...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international ...
Latest News
3 days ago · prnewswire.com
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needsThe new cobas ® eplex RP3 panel detects up to 19 viruses and bacteria, with newly added Bordetella pertussis and improved inclusivity of influenza A and SARS-CoV-2 strains, from a single sample to inform timely patient management. Laboratories can optimize resources with up to five flexible panel configurations tailored to local disease prevalence and patient needs, enabled by cobas® eplex system software version 3.0 or higher.
8 days ago · seekingalpha.com
Roche: Valuation Leaves Limited UpsideRoche delivered 7% Q3 sales growth at constant currency, although approximately CHF 180 million was attributable to shipments that had been brought forward in Japan. Pharmaceuticals performed well, but Chinese pricing reforms continue to weigh on Diagnostics, while FX remains a headwind to reported earnings. Giredestrant and fenebrutinib offer future growth opportunities, although regulatory approvals and commercial performance remain important uncertainties.
10 days ago · globenewswire.com
Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratoriesThe cobas smart e immunoanalyser - the newest addition to Roche's industry-leading cobas immunoassay systems portfolio - is engineered to deliver central-lab performance in a footprint under one square metre. With a planned menu of over 100 high-medical-value assays, and reaction times of 18 minutes or less for more than 90% of tests, the platform allows smaller laboratories to bring testing in-house, reducing turnaround times for patients.
10 days ago · globenewswire.com
Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two DecadesDENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews. com) - Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), AstraZeneca (NYSE: AZN), and Roche (OTCQX: RHHBY) are among the biopharma companies committing billions of dollars to new manufacturing facilities as obesity medicines become a major commercial opportunity.
11 days ago · fool.com
Breakfast News: Science Strikes Back at CancerCancer trial data shines at ESMO 2026, earnings flood after tough market week, and more…
11 days ago · wsj.com
Roche Targets Emerging Oncology Market With New Lung-Cancer DrugThe Swiss drugmaker expects a pill it is developing to become the new standard treatment for an advanced form of lung cancer, and the company's first shot at an emerging field within the oncology market.
11 days ago · reuters.com
Roche says divarasib cut risk of death 44% in lung cancer trialRoche says divarasib cut risk of death 44% in lung cancer trial
11 days ago · globenewswire.com
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancerBasel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).
13 days ago · businesswire.com
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Roche announced today late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P
13 days ago · globenewswire.com
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimised standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P
Add to Watchlist
Select watchlists to add or remove RHHBY